Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > 12/13 Goblet PC patients had Stage IV metastatic (M1) cancer

<< Previous

Bullboard Posts

Next >>

Comment by SundayMovieson Dec 06, 2022 3:28pm

129 Views

Post# 35154275

RE:RE:RE:RE:RE:RE:12/13 Goblet PC patients had Stage IV metastatic (M1) cancer

The press releases are too technical.

They should dum it up a bit by explaining what metastatic stage IV and all that nerdy stuff means so people can appreciate the info or not.

All that can fit in the note section with legal caviats.

Anyway, these people are very close to the end and somehow we got a complete response. I think it's actually the second instance here.
The first was recorded for one of the skin cancer duo trial earlier this year. So, something is working right...

We need those results!!! They need to be stellar!!!